NCT03604978 — National Cancer Institute (NCI) cancer immunotherapy trial
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
Registry record
| Registry ID | NCT03604978 ↗ |
|---|---|
| Lead sponsor | National Cancer Institute (NCI) |
| Collaborators | — |
| Phase | Phase 1/2 |
| Status | Active Not Recruiting |
| Indication | Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma |
| Enrollment | 38 participants (target) |
| Start date | 2019-06-17 |
| Primary completion | 2027-03-19 (est.) |
| Last registry update | 31 Jul 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT03604978), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
No modality, tumor or player hub covers this study yet. Browse the field map for the axes the daily brief does track.
Related trials
FAQ
What phase is NCT03604978?
NCT03604978 (Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma) is registered on ClinicalTrials.gov as Phase 1/2, sponsored by National Cancer Institute (NCI).
Is NCT03604978 recruiting?
As of the 2026-07-31 registry update, NCT03604978 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT03604978?
The lead sponsor is National Cancer Institute (NCI).
What condition does NCT03604978 study?
The registered conditions are Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma. Primary completion is listed as 2027-03-19 (estimated).
Are results available for NCT03604978?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT03604978.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.